Login
Goodbye job applications, hello dream career
Seize control of your career and design the future you deserve with 
Bakers and Clutz advise on pharmaceutical offload
Baker & McKenzie and Clayton Utz advise on the sale of Australian-based iNova Pharmaceuticals to Canada-based Valeant Pharmaceuticals.
Digital
Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital)
You’re out of free articles for this month
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: NYSE-listed, Canada-based Valeant Pharmaceuticals acquisition of Australian-based iNova Pharmaceuticals from Ironbridge and Archer Capital. Deal officially closed on 21 December
Advertisement
Advertisement
Area: M&A
Value: $625 million upfront and up to an additional $75 million in potential milestones
Key players: The Bakers team was led by Sydney-based partner David Egan and associate Michael Dearden
You need to be a member to post comments. Become a member for free today!
